Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

@article{Kerkel2006CardiotoxicityOT,
  title={Cardiotoxicity of the cancer therapeutic agent imatinib mesylate},
  author={Risto Kerkel{\"a} and Luanda P Grazette and Rinat Yacobi and Cezar A Iliescu and Richard D Patten and Cara Beahm and Brian Walters and Sergei P Shevtsov and St{\'e}phanie Pesant and Fred J. Clubb and Anthony Rosenzweig and Robert N. Salomon and Richard A. Van Etten and Joseph Alroy and Jean Bernard Durand and Thomas L. Force},
  journal={Nature Medicine},
  year={2006},
  volume={12},
  pages={908-916}
}
Imatinib mesylate (Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia. Here we report ten individuals who developed severe congestive heart failure while on imatinib and we show that imatinib-treated mice develop left ventricular contractile dysfunction. Transmission electron micrographs from humans and mice treated with imatinib show mitochondrial abnormalities and accumulation of membrane whorls in both vacuoles and the sarco… 
Targeted therapy: Stressed out hearts
TLDR
The authors found that JNK was activated in the hearts of imatinib-treated mice and that this activation was reduced by treatment with salubrinal, a small-molecule inhibitor of EIF2α dephosphorylation, which suggests that the inhibition of ABL by imatinIB is the mechanism of cardiomyocyte toxicity.
Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity.
TLDR
It is demonstrated that imatinib mesylate influences mitochondrial signaling leading to mitochondrial dysfunction and cardiotoxicity in H9c2 rat cardiomyocyte-like cells, and inhibition of Sab-related signaling partially rescued deficits in mitochondrial respiration, ATP production, and membrane potential inImatinib Mesylate-treated H9C2 cells.
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
TLDR
Evidence suggests that the three tyrosine kinase inhibitors currently approved for the treatment of patients with chronic myelogenous leukemia have potential cardiotoxic effects and should be considered in the management of CML.
Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.
  • Wenyue Hu, Shuyan Lu, +5 authors B. Jessen
  • Biology, Medicine
    Toxicological sciences : an official journal of the Society of Toxicology
  • 2012
TLDR
The results from these studies strongly suggest that imatinib induces cardiomyocyte dysfunction through disruption of autophagy and induction of ER stress, independent of c-Abl inhibition.
Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
TLDR
Imatinib is a potent anti-inflammatory and anti-fibrotic drug, and might be a promising candidate for the treatment of rheumatoid arthritis and systemic sclerosis.
A Multifaceted Evaluation of Imatinib-induced Cardiotoxicity in the Rat
TLDR
The authors conclude that Imb exerts cardiotoxic effects that are manifest through a complex pattern of cellular alterations, the severity of which can be influenced by arterial blood pressure.
Drug adaptation influences cardiotoxicity caused by tyrosine kinase inhibitors in iPSC-derived human cardiomyocytes
TLDR
The response of cardiomyocytes to Sorafenib is characterized by adaptive drug resistance previously described in tumor cells, and the effect is reversible upon drug withdrawal.
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
TLDR
It is found that untreated GIST cells down-regulate H2AX in a pathway that involves KIT, phosphoinositide-3-kinase, and the ubiquitin/proteasome machinery, and that the imatinib-mediated H2 AX up-regulation correlates with imatin ib sensitivity.
Imatinib mesylate induces necroptotic cell death and impairs autophagic flux in human cardiac progenitor cells
TLDR
Imatinib applied to human cardiac progenitor cells depolarizes mitochondria and induces cell death through necroptosis, which can be recovered by inhibition of RIP1, with an additional partial role for autophagy in the cell death pathway.
Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II
TLDR
Findings highlight a new role for CaMKII in TKI-induced cardiotoxicity, particularly at the level of the mitochondria, and confirm differential off-target toxicity in CFs, consistent with the differential selectivity of sunitinib and imatinib.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 59 REFERENCES
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
TLDR
The preclinical profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval are described and the basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
TLDR
The preclinical and clinical development of imatinib for the therapy of CML, resistance and strategies that may help to eliminate resistant or residual leukemia are reviewed.
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy.
TLDR
Anti-erbB2 activates the mitochondrial apoptosis pathway through a previously undescribed modulation of Bcl-xL and -xS, causing impairment of mitochondrial function and integrity and disruption of cellular energetics.
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
TLDR
The data indicate that fibroblasts respond to TGF-beta by stimulating c-Abl kinase activity independently of Smad2/3 phosphorylation or PDGFR activation, and that Abl family members represent common targets for the modulation of profibrotic cytokine signaling.
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
TLDR
The utility of this murine model of CML in the evaluation of novel therapeutic agents against Bcr/Abl-induced leukemias is demonstrated and this improved murine chronic-phase CML model may be a useful tool for the study of STI571 resistance, CML progression, and the anti-CML immune response.
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
TLDR
It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested.
A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.
TLDR
The results suggest that imatinib mesylate induces a caspase-independent, necrosis-like programmed cell death mediated by the serine protease activity of Omi/HtrA2.
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy.
  • A. Sanbe, H. Osińska, +5 authors J. Robbins
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2005
TLDR
It is shown that aggresome levels do not correlate with disease, and blocking cardiac amyloid oligomer formation, even after cardiac dysfunction presents, may be a therapeutic strategy in DRM as well as in other types of cardiac disease in which significant amyloids accumulation occurs.
Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity
TLDR
The increased susceptibility of myofilaments to doxorubicin in the presence of antibody to erbB2 may explain the contractile dysfunction seen in patients receiving concurrent trastuzumab and anthracyclines.
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
TLDR
Evaluated antineoplastic activity of CGP57148B indicates that the continuous block of the oncogenic tyrosine kinase of Bcr/Abl protein is needed to produce important biologic effects in vivo.
...
1
2
3
4
5
...